Invariant NK T (iNKT) cells are known to play a critical role in the regulation of inflammatory responses in various clinical settings. In the present study, we assessed the contribution of iNKT cells to the development of acute lung injury (ALI), which was caused by intra-tracheal administration of LPS. Ja18 gene-disrupted mice lacking these cells underwent neutrophilic inflammatory responses in lungs at an equivalent level as control mice. Next, mice were sensitized intra-tracheally with a-galactosylceramide, an activator of iNKT cells, followed by challenge with LPS. In this model, mice showed severe lung injury, and all mice were killed within 72 h after LPS injection. IFN-g and tumor necrosis factor (TNF)-a were strikingly elevated in the lungs of these mice. Administration of neutralizing mAb against IFN-g and TNF-a attenuated lung injury in a histopathological analysis and improved their survival rate. Flow cytometric analysis revealed that IFN-g was expressed in NK cells, iNKT cells and also Gr-1 dull1 Ly-6C 1 monocytes and TNF-a was detected mainly in Gr-1 bright1 Ly-6G 1 neutrophils and Gr-1 dull1 Ly-6C 1 monocytes. Otherwise, in mice treated with LPS alone, IFN-g was not detected in the lungs and Gr-1 bright1 Ly-6G 1 neutrophil was a main cellular source of TNF-a production. Anti-Gr-1 mAb resulted in the attenuation of ALI and decrease in the level of these cytokines. These results indicated that activation of iNKT cells led to striking exacerbation of ALI caused by LPS and that Gr-1 1 monocytes were recruited in the lungs with expressing IFN-g and TNF-a and played an important role in the development of these responses.
Introduction
Acute lung injury/acute respiratory distress syndrome (ALI/ ARDS) was defined by the 1994 American-European Consensus Conference as a syndrome of reduced pulmonary gas exchange caused by diffuse inflammatory processes with increased vascular permeability. Each of these commonly associated clinical disorders is divided into cases of direct injury to the lung and cases in which indirect lung injury occurs in the context of a systemic process (1) . Causes of direct injury include infection with severe acute respiratory syndrome (SARS) virus (2) or avian influenza A H5N1 virus (3) in the lung, either of which results in high mortality among humans due to ARDS as a complication. The serum levels of the cytokines IFN-c, tumor necrosis factor (TNF)-a and IL-6 increase in cases of fatal human H5N1 influenza virus infection (4) (5) (6) and the concentrations in the bronchoalveolar lavage (BAL) fluids of several cytokines, including TNF-a, IL-1b, IL-6, IL-8 and IL-10, increase dramatically in cases of acute-phase ARDS (7) (8) (9) . It is believed that these inflammatory cytokines are important pathogenic factors involved in the development of ALI/ARDS.
NKT cells, which express both TCRab and NK markers, have been identified as a novel lymphocyte population that acts in innate immune responses (10) . These cells recognize glycolipid antigens such as a-galactosylceramide (a-GalCer) in the context of CD1d molecule expression on dendritic cells (DCs); this results in the rapid production of various cytokines, including interferon (IFN)-c and IL-4 (11) (12) (13) (14) . There is some controversy regarding the contribution of NKT cells to the pathogenic mechanism in mouse models of sepsis. Dieli et al. (15) have demonstrated that NKT cells play an essential role as a source of IFN-c in the development of generalized Shwartzman reactions. On the other hand, Emoto et al. (16) found that LPS-induced shock could be successfully induced in the absence of NKT cells and that IFN-c from NK cells is instead involved in the pathogenic mechanism of lethal shock in mice. Interestingly, sensitization with a-GalCer, a strong activator of NKT cells, renders mice highly susceptible to indirect lung injury caused by systemic injection of LPS, which is associated with increased levels of IFN-c and TNF-a in the circulation (17) . This recent discovery suggests a possible involvement of NKT cells in the development of ALI/ARDS associated with sepsis, although no evidence for this based on animal models of direct lung injury has yet been reported.
Marginated leukocytes produce a highly localized and focused release of inflammatory and injurious mediators; lung margination of leukocytes, and particularly that of neutrophils, is considered to play a major role in the pathogenesis of ALI (18) . Recent studies have found that monocytes also marginate to the lungs during systemic inflammation and have the ability to trigger the release of a variety of cytokines and chemokines (19, 20) . Peripheral blood monocytes in mice are a pluripotent and heterogeneous population consisting of two phenotypically distinct subsets. Immature monocytes, which express Gr-1 high CCR2 + CXCR1 low , enter the circulation from bone marrow and migrate into local sites of inflammation and injury. Mature monocytes, which express Gr-1 low CCR2 À CXCR1 high , are capable of entering the tissues under resting conditions as well as under local inflammatory conditions and have the potential to differentiate into lung macrophages (21, 22) . In a mouse model of LPS-induced sepsis-related ALI, mobilization and margination of Gr-1 high monocytes during subclinical endotoxemia make the lungs more sensitive to further septic stimuli; accordingly, this monocyte subset is suggested to play a central role in the development of ALI (20) . However, the role of Gr-1 + monocytes in direct lung injury remains to be completely elucidated.
Based on these earlier findings, we investigated in the current study how the activation of iNKT cells by intratracheal administration of a-GalCer affected the clinical course of and histopathological changes associated with direct lung injury caused by intra-tracheal instillation of LPS in mice. We found that a-GalCer-sensitized mice were highly susceptible to LPS-induced ALI/ARDS. In addition, we examined the role of cytokines such as IFN-c and TNF-a in the development of ALI/ARDS and addressed the possible contribution of Gr-1 + monocytes to the production of these cytokines and to the development of this pathogenic condition.
Materials and Methods

Animals
Va14+ NKT cell-deficient mice (Ja18KO mice) were established through targeted deletion of the Ja18 gene segment (23) . C57BL/6 and Ja18KO mice were bred in a pathogenfree environment at the Institute for Animal Experimentation, Tohoku University Graduate School of Medicine. All mice were used for experiments at 6-8 weeks of age. All experimental protocols described in the present study were approved by the Ethics Review Committee for Animal Experimentation of Tohoku University.
Induction of LPS-mediated ALI/ARDS model in mice
a-GalCer was purchased from Funakoshi (Tokyo, Japan) and dissolved in dimethyl sulfoxide (DMSO) at 5 mg ml À1 and then diluted with PBS to a final dose of 0.4% DMSO for in vivo use. LPS from Escherichia coli (O111: B4) was purchased from Sigma-Aldrich (St Louis, MO, USA). To induce lung injury, mice anesthetized by intra-peritoneal injection of 70 mg kg À1 of pentobarbital (Abbott Laboratories, North Chicago, IL, USA) were restrained on a small board, and 50 ll of either a-GalCer (1lg) or 0.4% DMSO-containing PBS (dPBS) as a vehicle control was injected into each mouse by insertion of a 24-gauge intravenous catheter (TERUMO, Tokyo, Japan) into the trachea. Twenty-four hours later, 50 ll of LPS (50 lg) was administered via the same route. In some experiments, mice were injected intra-tracheally with 200 ng of recombinant IFN-c (purchased from PeproTech, Inc., Rocky Hill, NJ, USA), either 24 h before LPS challenge, together with LPS, or together with LPS and 2 lg of human TNF-a purified from a Bcell lymphoblastoid cell line (BALL-1) (24) [a gift of Hayashibara Biochemical Laboratories Inc. (Okayama, Japan)].
Wet/dry lung weight ratio
The lungs of mice treated with a-GalCer or dPBS were weighed 48 h after LPS challenge to determine the final wet lung weight. They were then dried in an oven at 60°C for 48 h and weighed again to determine the dry weight. The wet/dry (W/D) weight ratio was then calculated.
Histological Examination
The lung specimens obtained from mice were fixed in 10% buffered formalin, dehydrated and embedded in paraffin. Sections were cut and stained with hematoxylin-eosin (H-E) and Elastica-Masson stains using standard staining procedures at Biomedical Research Core, Animal Pathology Platform of Tohoku University Graduate School of Medicine.
was infused intra-tracheally and withdrawn. This procedure was performed three times to remove the cells in the alveolar space. The pulmonary circulation was then rinsed to remove non-adherent cells from the pulmonary vessels by injection of 3 ml PBS into the right ventricle. Next, lungs were harvested and stored, either in 1.5 ml PBS for analysis of cytokines in the interstitial area of lungs or in the same volume of RPMI1640 medium supplemented with 10% FCS for analysis of the lung interstitial leukocytes. The lungs in PBS were homogenized and centrifuged at 1600 r.p.m. for 10 min at 4°C, and the supernatants were stored at À80°C until cytokines were measured. For analysis of the expression of surface antigens, the homogenized lung cells were incubated in RPMI1640 medium supplemented with 10 mM HEPES and 10% FCS and containing 20 U ml À1 collagenase (SigmaAldrich) and 1 lg ml À1 DNase I (Sigma-Aldrich) for 60 min at 37°C with vigorous shaking. Tissue fragments and dead cells were removed by passing the solution through 40-lm nylon mesh. After centrifugation at 1600 r.p.m. for 5 min at 4°C, each cell pellet was re-suspended in 4 ml of 40% (v/v) Percoll (Pharmacia, Uppsala, Sweden) and layered onto 4 ml of 80% (v/v) Percoll. After centrifugation at 1600 r.p.m. for 20 min at room temperature, the cells at the interface were collected, washed three times and counted with a hemocytometer. The cells that were obtained through this process included lymphocytes, macrophages and neutrophils.
Analysis of cell surface antigens and intracellular cytokines
The lung interstitial leukocytes were pre-incubated with antiFccRIII mAb, prepared from the culture supernatants of hybridoma cells (clone 2.4G2) using a protein G column kit (Kirkegaard & Perry Laboratories, Gaithersburg, MD, USA), on ice for 15 min in PBS containing 1% FCS (Cansera, Rexdale, Ontario, Canada) and 0.1% sodium azide. The cells were stained with FITC-conjugated anti-CD11c mAb (clone HL3; BD Biosciences, Franklin Lakes, NJ, USA), PEconjugated anti-NK1.1 mAb (clone PK136; e-Bioscience, San Diego, CA, USA), anti-Gr-1 mAb (clone RB6-8C5; e-Bioscience), anti-CD11b mAb (clone M1/70; BD Biosciences), anti-F4/80 mAb (clone BM8; BD Biosciences), anti-Ly-6C mAb (clone 1G7.G10; Miltenyi Biotec, Bergisch Gladbach, Germany) and anti-Ly-6G mAb (clone 1A8; Miltenyi Biotec) and allophycocyanin (APC)-conjugated anti-Gr-1 mAb (clone RB6-8C5; e-Bioscience) and anti-TCRb mAb (clone H57-597; e-Bioscience) or appropriate isotype-matched control. After cell surfaces were stained and cells were washed twice, intracellularly expressing cytokines were stained according to the following method: cells were incubated in the presence of cytofix/cytoperm (BD Biosciences), washed twice in BD perm/wash solution and stained with FITC-conjugated anti-IFN-c or anti-TNF-a mAb (clone XMG1.2 or clone MP6-XT22; BD Biosciences) or control rat IgG (clone R3-34, BD Biosciences). Brefeldin A was not used because freshly isolated cells from lungs were stained for intracellular cytokine expression. The stained cells were analyzed using a flow cytometer (Cytomics FC500; Beckman Coulter, Inc., Fullerton, CA, USA). Data were collected from 30 000 individual cells using parameters of forward scatter (FSC) and side scatter (SSC) to limit the lymphocyte, macrophage or neutrophil population.
Measurement of cytokine concentrations
The concentrations of IFN-c and TNF-a in the supernatants of lung homogenates were measured by means of ELISA using capture and biotinylated developing antibodies (BD Biosciences). The concentrations of macrophage inflammatory protein (MIP-2) and macrophage chemoattractant protein-1 (MCP-1) were measured using ELISA kits [R&D Systems (Minneapolis, MN, USA) and e-Bioscience, respectively]. The detection limits were 15, 5, 1.5 and 15 pg ml
À1
, respectively.
Administration of Antibodies
Anti-IFN-c, anti-TNF-a and anti-Gr-1 mAbs were purified from culture supernatants of hybridoma [clones R4-6A2, MP6-XT2.2-11 and RB6-8C5, respectively (anti-TNF-a mAb was a gift of Dr Akio Nakane, Hirosaki University Graduate School of Medicine, Hirosaki, Japan; anti-IFN-c mAb was a gift of Dr Fujiro Sendo, Yamagata University, Yamagata, Japan)] using a protein G column kit (Kierkegaard & Perry Laboratories). To neutralize the biological activity of IFN-c and TNF-a, mice were injected intra-peritoneally with 200 lg each of mAbs against these cytokines at 24 h before and 0 and 24 h after LPS challenge. To eliminate Gr-1 cells, mice received intra-peritoneal injections of 200 lg of mAb against this molecule at 24 h before and 0 and 24 h after LPS challenge. Rat IgG (ICN Pharmaceuticals, Inc., Aurora, OH, USA) was used as a control antibody.
Statistical analysis
Analysis of data was conducted using StatView II software (Abacus Concepts, Inc., Berkeley, CA, USA) on a Macintosh computer. Data are expressed as mean 6 SD. Statistical analysis between groups was performed using analysis of variance with a post hoc analysis (Fisher's Protected Least Significant Difference test). Survival data were analyzed using the generalized Wilcoxon test. A P value <0.05 was considered significant.
Results
Role of iNKT cells in LPS-induced ALI
In order to elucidate the role of iNKT cells in LPS-induced lung injury, Ja18KO and wild-type (WT) mice were compared in their survival and lung inflammatory responses after intratracheal instillation of LPS. No mice were dead in both groups during the observation period until day 14 after LPS instillation. As shown in Fig. 1(A and B) , the number of neutrophils and concentration of TNF-a and MIP-2 in BAL fluids were almost equivalent between Ja18KO and WT mice instilled intra-tracheally with LPS. These results indicate that iNKT cells do not play an essential role in the development of ALI caused by intra-tracheal administration of LPS.
Fatal ALI/ARDS caused by intra-tracheal administration of LPS in a-GalCer-sensitized mice
In our earlier studies (26, 27) , iNKT cells contribute to the neutrophilic inflammatory responses in lungs after infection with Streptococcus pneumoniae. In the next series of experiments, we addressed a question whether activation ALI in NKT cell-activated mice 99 of iNKT cells affect the clinical course of LPS-induced ALI. For this purpose, mice were sensitized by intra-tracheal administration of a-GalCer and then given LPS via the same route 24 h later. dPBS was used as a vehicle control for a-GalCer. As shown in Fig. 2 (A), all mice pre-treated with dPBS remained alive during the observation period after LPS challenge, whereas all mice pre-treated with a-GalCer were dead within 72 h of LPS challenge. The effect of a-GalCer was completely abrogated in Ja18KO mice. To evaluate pulmonary edema at 48 h after LPS challenge in a-GalCer-or PBS-sensitized C57BL/6 and Ja18KO mice, we examined the wet/dry lung weight ratios (Fig. 2B ). The ratios were significantly higher in C57BL/6 mice sensitized with a-GalCer than in C57BL/6 mice pre-treated with dPBS, whereas this elevation was almost completely absent in Ja18KO mice.
Next, we performed histopathological analyses to identify the inflammatory changes in this model. As shown in Fig. 2 (C), mild alveolitis with neutrophilic infiltration was observed in mice pre-treated with dPBS before LPS challenge, whereas these responses were much more pronounced in mice sensitized with a-GalCer before LPS challenge: a large number of neutrophils were seen to have infiltrated not only into the intra-alveolar septa but also into the alveolar spaces; in addition, alveolar hemorrhage was more broadly observed. In addition, hyaline membrane formation, a typical histopathological finding associated with ARDS, was detected via Elastica-Masson staining in mice sensitized with a-GalCer before LPS challenge (Fig. 2D ). These results indicate that sensitization of mice with an iNKT cell activator lead to the exacerbation of LPS-induced ALI into much severe condition, similar to ARDS.
Production of IFN-c during the development of ALI/ARDS
It is well documented that iNKT cells quickly produce large amounts of IFN-c in response to a-GalCer. Because this lymphocyte subset occurs as a very small population in the lungs (26) , however, we initially examined whether IFN-c was induced by intra-tracheal administration of a-GalCer. As shown in Fig. 3(A) , concentrations of IFN-c in the lung homogenates of a-GalCer-treated C57BL/6 mice were elevated 2-fold compared with those of dPBS-treated C57BL/6 mice; this elevation was not detected in Ja18KO mice.
In the next set of experiments, we addressed whether IFNc synthesis in the lungs was further increased by a challenge with LPS. For this purpose, concentrations of IFN-c were measured at 6 h after LPS challenge in a-GalCer-or dPBS-pretreated C57BL/6 and Ja18KO mice. As shown in Fig. 3(B) , IFN-c production in the lung homogenates of a-GalCersensitized C57BL/6 mice was elevated 5-fold compared with that in dPBS-pre-treated mice; this elevation was not detected in Ja18KO mice. These results indicate that IFN-c is produced during sensitization with a-GalCer and that its production is enhanced at the time of LPS challenge, suggesting that this cytokine may play an important role in the development of ALI/ARDS.
Role of IFN-c in the development of ALI/ARDS
In order to address this possibility, we examined the effect of a neutralizing anti-IFN-c mAb treatment on survival rates and histopathological changes in the lungs of a-GalCer-sensitized LPS-treated mice. As shown in Fig. 4(A) , all mice treated with anti-IFN-c mAb survived at least until the end of the observation period, whereas 87.5% of mice treated with control rat IgG died by day 3 post-LPS challenge. According to our histopathological analysis, inflammatory changes and alveolar hemorrhage were attenuated in mice treated with anti-IFN-c mAb compared with mice treated with control rat IgG (Fig. 4B) . These results indicate that IFN-c plays a pivotal role in LPS-induced ALI/ARDS in a-GalCer-sensitized mice and suggest that this cytokine may be involved in producing the sensitization effects of a-GalCer.
To address this possibility, the next set of experiments examined whether a-GalCer could be replaced by IFN-c during the sensitization process. Mice were treated with rIFN-c in place of a-GalCer before challenge with LPS; their survival rate was then examined and histopathological analyses were conducted on their lungs. Fifty percent of mice treated sequentially with IFN-c and LPS were dead within 48 h, whereas all mice treated with either IFN-c or LPS alone survived (data not shown). As shown in Fig. 5(A) , rIFN-c-sensitized mice exhibited lung injury characterized by neutrophilic infiltration and hemorrhagic changes that were as severe as those seen in a-GalCer-sensitized mice at 48 h post-LPS challenge. These changes were also observed when mice were treated with rIFN-c simultaneously with LPS, although the changes were less pronounced. These results suggest that the sensitization process may be mediated, at least in part, by IFN-c.
In our previous study, we found that iNKT cells play an important role in host defense against pneumococcal pneumonia by inducing IFN-c production, which leads to the synthesis of TNF-a. Therefore, we measured the concentrations of TNF-a in the lung homogenates of mice treated with either rIFN-c or LPS or both. As shown in Fig. 5(B) , the administration of rIFN-c followed by LPS resulted in the production of huge amounts of TNF-a, whereas much smaller amounts of TNF-a were produced in mice treated with rIFN-c alone, LPS alone or even both simultaneously. These results suggest that TNF-a may be involved in the development of ALI/ARDS in this model.
Role of TNF-a in the development of ALI/ARDS
In order to elucidate the role of TNF-a, we evaluated the production of TNF-a in lungs during the development of ALI/ ARDS. As Fig. 6 dramatically shows, TNF-a production in the lung homogenates of a-GalCer-sensitized mice was elevated 4-fold compared with that in dPBS-pre-treated mice at 6 h post-LPS treatment; this elevation was not detected in Ja18KO mice. This observation suggests that TNF-a is deeply involved in the development of ALI/ARDS. To confirm this, we next examined the effect of anti-TNF-a mAb treatment on the survival rates and histopathological changes in the lungs of a-GalCer-sensitized LPS-treated mice. As shown in Fig. 7(A) , the survival rate of mice treated with anti-TNF-a mAb was much higher than that of mice treated with control rat IgG. According to our histopathological analysis, inflammatory changes and alveolar hemorrhages were attenuated in mice treated with anti-TNF-a mAb compared with those in mice treated with control rat IgG (Fig. 7B) .
In the next set of experiments, we examined whether treatment with TNF-a could promote the development of ALI/ARDS triggered by LPS, as we had seen that treatment with a-GalCer could. Mice that had not been sensitized with a-GalCer were treated with either LPS or TNF-a or both simultaneously. Their survival rate was examined and WT and Ja18KO mice that had been sensitized with a-GalCer or dPBS were administered LPS intratracheally; 6 h later, concentrations of IFN-c in the lung homogenates were measured. Each column represents the mean 6 SD of five mice; *P < 0.05. ALI in NKT cell-activated mice 101 histopathological analyses were conducted on their lungs. Although no mice in any of these groups died within 3 days post-treatment (data not shown), lung injury characterized by neutrophilic infiltration and hemorrhagic changes was observed in mice treated with both LPS and TNF-a, whereas much less severe histopathological changes were observed in mice treated with either agent alone (Fig. 8) . These results indicate that TNF-a plays a pivotal role in LPS-induced ALI/ARDS in a-GalCer-sensitized mice.
Cellular source of IFN-c and TNF-a during the development of ALI/ARDS
To determine the cellular source of early production of IFN-c, we used flow cytometry to examine the expression of this cytokine in the inflammatory leukocytes recruiting in the lungs, including neutrophils, macrophages and lymphocytes; each type was gated in the FSC/SSC scattergram Fig. 6 . Production of TNF-a in the lungs of a-GalCer-sensitized and LPS-challenged mice. WT and Ja18KO mice were sensitized with a-GalCer or dPBS, then administered LPS 24 h later; concentrations of TNF-a in the lung homogenates were measured 6 h after LPS treatment. Each column represents the mean 6 SD of five mice; *P < 0.05. (R1, R2 and R3, respectively, in Fig. 9A ). First, we analyzed the expression of IFN-c in iNKT cells and NK cells, shown as NK1.1 + TCRb + and NK1.1 + TCRb À cells, in the R3 region at 3 h after LPS challenge in a-GalCer-sensitized or dPBS-pre-treated mice. As shown in Fig. 9(A) , higher rates of IFN-c expression were detected in both cell types in a-GalCer-sensitized mice compared with dPBS-pre-treated mice [12.6 6 4.8% versus 3.0 6 2.3% in iNKT cells (n = 3 each) and 40.5 6 16.3% versus 1.3 6 0.6% in NK cells (n = 3 each), P < 0.05 in both cell types]. Next, we tested whether myeloid cells, shown as Gr-1 + cells, also expressed IFN-c because this population was increased during sensitization with a-GalCer (Supplementary Figure 1 is available at International Immunology Online). As shown in Fig. 9(B) , Gr-1 + cells in the R1 region were not likely to express IFN-c, whereas Gr-1 dull+ cells in the R2 region showed IFN-c expression after LPS challenge at a higher proportion in a-GalCer-sensitized mice than in dPBS-pre-treated mice [31.5 6 6.3% versus 12.2 6 3.1% (n = 3 each), P < 0.05].
These results indicate that Gr-1 dull+ cells as well as iNKT and NK cells contribute to IFN-c production during the development of ALI/ARDS.
In the next series of experiments, we addressed the cellular source of TNF-a production. Neither iNKT cells nor NK cells in the R3 region expressed this cytokine at 3 h after LPS challenge (data not shown). As shown in Fig. 9(C) , there was a significant difference between the levels of TNF-a expressed by Gr-1 + cells in the R1 region in a-GalCersensitized mice and those expressed in dPBS-pre-treated mice, although the values are small [6.5 6 1.6% versus 2.2 6 0.6% (n = 3 each), P < 0.05], whereas Gr-1 dull+ cells in the R2 region expressed this cytokine at a higher proportion in a-GalCer-sensitized mice than in dPBS-pre-treated mice [23.4 6 5.7% versus 12.5 6 2.5% (n = 3 each), P < 0.05]. These results indicate that Gr-1 dull+ cells play an important role in the production of TNF-a during the development of ALI/ARDS. There were two different patterns, bright and dull positive, in the expression of Gr-1 in the R1 and R2 regions. To characterize the Gr-1 bright+ and Gr-1 dull+ cells, we further examined other cell surface markers including CD11c, CD11b, Ly-6C, Ly-6G and F4/80. As shown in Fig. 9(D 
Ly-6C
+ Ly-6G À F4/80 + cells, indicating that the former population represents neutrophils while the latter represents macrophages. Additionally, the cell population in the R1 region was mostly characterized as neutrophils, as shown in Supplementary Figure 3 (available at International Immunology Online).
Effect of Gr-1 + cell depletion on the development of ALI/ARDS
In order to elucidate the role of Gr-1 + cells in the development of ALI/ARDS, we examined the effect of anti-Gr-1 mAb administration on the survival rates, histopathological findings and cytokine production levels in a-GalCer-sensitized LPS-treated mice. By this treatment, both Gr-1 dull+ and Gr-1 bright+ cells were deleted and strongly reduced, respectively, as shown in Supplementary Figure 4 (available at International Immunology Online). As shown in Fig. 10(A) , 87.5% of mice treated with anti-Gr-1 mAb survived throughout the observation period, whereas only 12.5% of mice treated with control rat IgG survived. According to our histopathological analysis, inflammatory changes and alveolar hemorrhages were attenuated in mice treated with anti-Gr-1 mAb compared with those in mice treated with control rat IgG (Fig. 10B) . Finally, production levels of IFN-c and TNF-a in the lungs were significantly lower in mice treated with anti-Gr-1 mAb than in mice treated with control rat IgG (Fig.  10C and D) . In particular, anti-Gr-1 mAb treatment reduced TNF-a production to a level almost equivalent to that seen in mice treated with LPS alone but not sensitized with a-GalCer (Fig. 10C) . These results indicate that Gr-1 + cells play a critical role in the production of IFN-c and TNF-a and in the development of ALI/ARDS.
Discussion
The major findings of the present study are as follows: (i) Ja18KO and WT mice were almost equivalent in the clinical course and neutrophilic inflammatory responses in lungs after intra-tracheal administration of LPS; (ii) sensitization with a-GalCer caused a fatal clinical outcome and acute and robust inflammatory responses with hyaline membrane formation in the lungs of mice that were subsequently given LPS intra-tracheally, whereas this pattern was completely abrogated in Ja18KO mice; (iii) LPS-induced production of IFN-c and TNF-a in lungs was strikingly accelerated by sensitization with a-GalCer, whereas such enhancement was not seen in Ja18KO mice; (iv) administration of neutralizing mAbs against either IFN-c or TNF-a resulted in improved survival rates and less marked inflammatory responses in lungs; (v) sensitization with rIFN-c before LPS challenge or co-administration of TNF-a together with LPS caused a robust accumulation of inflammatory leukocytes in lungs, in a response similar to that observed in mice sensitized with a-GalCer and then challenged with LPS; (vi) according to flow cytometric analysis, IFN-c was expressed in NK and iNKT cells as well as in Gr-1 dull+ Ly-6C + monocytes, whereas Gr-1 bright+ Ly-6G + neutrophils and Gr-1 dull+ Ly-6C + monocytes were the cellular sources for TNF-a synthesis and (vii) depletion of Gr-1 + cells by specific mAb resulted in improved survival rates, less pronounced histopathological changes and reduced production of IFN-c and TNF-a in mice sensitized with a-GalCer and then challenged with LPS. These results indicate that intrapulmonary activation of iNKT cells strikingly accelerates the progression of ALI/ARDS triggered by LPS, which is associated with enormous production levels of IFN-c and TNF-a as well as acute and robust accumulation of inflammatory leukocytes in lungs.
In human ARDS, the histological characteristics are (i) loss of alveolar-capillary barrier, as vascular leak with flooding of the alveolar space with protein-rich edema fluid, (ii) alveolar epithelial injury, this damage to the alveolar epithelium impairs surfactant production with the accumulation of pulmonary edema, (iii) massive inflammatory cells accumulated into the air space and (iv) formation of hyaline membranes, which are a direct result of intra-alveolar fibrin polymerization (1, 28) . In models of direct pulmonary injury induced by intra-tracheal administration of LPS, acute and robust influx of inflammatory cells into the lungs is observed, but these inflammatory changes are completely resolved within 48 h, neither alveolar epithelial injury nor vascular leakage, typical features of ARDS, is observed (28, 29) . In this conventional model of ALI, any difference was not detected in the neutrophilc inflammatory responses in lungs between Ja18KO and WT mice, indicating that iNKT cells play a limited role in the development of ALI caused by LPS and suggesting that a certain additional factor is required for progressing into ARDS. In the current study, activation of intrapulmonary iNKT cells by a-GalCer before LPS challenge resulted in fatal clinical outcome, acute and robust inflammatory responses with hyaline membrane formation in the lungs and increase in the wet/dry lung weights, indicating the lung edema, similar to the findings of ARDS. Interestingly, systemic activation of iNKT cells by intra-peritoneal administration of a-GalCer did not cause these changes (data not shown). These observations suggest that intrapulmonary iNKT cells may be involved in the progression of ALI into more severe condition and that failure to detect the involvement of iNKT cells may account for less severe clinical outcome of ALI caused by LPS, which does not lead to the development of ARDS.
It is well documented that iNKT cell activation has been induced by a-GalCer in the context of CD1d on antigenpresenting cells and that this results in robust secretion of immunoregulatory cytokines, including both IFN-c and IL-4 (30) . iNKT cells play crucial immunoregulatory roles in a variety of pathological conditions in humans and mice, including infections and allergic diseases (31) . In the current study, the effects of a-GalCer sensitization on the progression of ALI/ ARDS were completely abrogated in Ja18KO mice, indicating that the activation of iNKT cells is involved in the lethal lung damage caused by LPS. IFN-c secretion by iNKT cells during various immune responses is reported to contribute to hostprotective responses against lung infectious diseases (27, 32) and to anti-fibrotic defense against bleomycin-induced pulmonary fibrosis (33) . Although the precise mechanism by which a-GalCer promotes the development of lethal response in the lungs remains to be clarified, the results of earlier investigations have suggested the involvement of this cytokine in lethal endotoxemia (34, 35) . In the current study, a-GalCersensitized mice exhibited an increase in IFN-c production in the lungs, and pre-treatment with IFN-c before LPS challenge led to histopathological changes that were drastic in comparison with those caused by LPS treatment alone. In addition, the neutralization of endogenously synthesized IFN-c by means of a specific mAb attenuated lung damage and prolonged survival after LPS challenge in a-GalCer-sensitized mice. These findings indicate that the ability of a-GalCer to promote the development of lung injury is mediated, at least in part, by the production of this cytokine, which is in agreement with earlier study by Ito et al. (17) using endotoxemia mice sensitized with a-GalCer.
It is known that the activation of iNKT cells by a-GalCer leads to the rapid production of IFN-c by NK cells as well as iNKT cells (36, 37) . In a previous study by Carnaud et al. (38) , a-GalCer leads to rapid production of IFN-c by NK cells, which is dependent on IFN-c secreted from activated iNKT cells. It is well documented that IFN-c stimulates macrophages to secrete IL-12 and IL-18 that induces the production of IFN-c by NK cells (39) . This mechanism may be operated in our model. Interestingly, in an LPS-induced sepsis model, NK cells rather than NKT cells are the most important source of endogenous IFN-c synthesis; furthermore, they play a critical role in the pathogenic mechanism underlying this condition (16, 40) . In our model, the proportions of NK and iNKT cells expressing IFN-c were increased at 3 h after LPS challenge in the lungs of a-GalCer-sensitized C57BL/6 mice. Thus, our results suggest that NK cells as well as iNKT cells may contribute to the development of ALI/ ARDS in our model by inducing IFN-c production.
Pro-inflammatory cytokines such as TNF-a and IL-1b are derived predominantly from activated macrophages and act by binding to their specific receptors during the progression of ALI/ARDS (41, 42) . In particular, the administration of TNFa causes a pathogenic condition that is indistinguishable from septic shock in experimental animals (8) . In the current model, excessive production of TNF-a in the lungs was likely correlated to the accumulation of inflammatory cells and damage to lung tissues, strongly suggesting a contribution of TNF-a to the development of ALI/ARDS. In keeping with this possibility, neutralization of this cytokine by specific mAb led to reduce lung damage and rates of fatal clinical outcome in a-GalCer-sensitized LPS-challenged mice. Interestingly, the improvement in survival rate associated with anti-TNF-a mAb was less marked than that associated with anti-IFN-c mAb ( Figs 3A and 6A) , and concentrations of TNF-a in the lung homogenates were not affected by the administration of anti-IFN-c mAb at 6 h after LPS challenge in a-GalCer-sensitized mice (data not shown). These results suggest that IFN-c may play a more pivotal role in the progression of lethal ALI/ARDS than TNF-a does. In agreement with this notion, Ito et al. (17) reported that neutralizing anti-IFN-c mAb more clearly improved the lethal outcome than anti-TNF-a mAb in endotoxemia mice sensitized with a-GalCer.
Previous investigations have shown that the alveolar macrophages that produce TNF-a play a critical role in regulating recruitment and activation of monocytes and neutrophils, which are essential for the progression of ALI caused by LPS (1, 18, 43) . Neutrophils also have the ability to produce TNF-a upon stimulation with LPS (44) (45) (46) . Aerosolized LPS induces consistent migration of these cells expressing Gr-1 into all lung compartments and sequestration into the alveolar space (47) . The role of TNF-a-producing neutrophils, however, has not previously been elucidated in animal models of ALI/ARDS. In the current study, by contrast, not only neutrophils (identified as Gr-1 bright+ Ly-6G + cells) but also myeloid cells with the Gr-1 dull+ Ly-6C + F4/80 + phenotype contributed to the production of TNF-a. Interestingly, Gr-1 dull+ cells were not found in BAL fluids, although they were detected among the interstitial lung cells; this suggests that these cells may be trapped by alveolar/epithelial barrier, as previously reported in a mouse model of sepsis (20) . In addition, a-GalCer-sensitized LPS-challenged mice expressed intracellular IFN-c in Gr-1 dull+ cells as well as in iNKT and NK cells but not in Gr-1 bright+ neutrophils. The mechanism of IFN-c production by Gr-1 dull+ cells following NKT cell activation remains to be clarified. In previous studies (48), Gr-1+ monocytes accumulate at inflammatory sites and differentiate into pulmonary DCs, and myeloid DCs and macrophages produce IFN-c in response to IL-12 and IL-18 (49) . These previous findings suggest that Gr-1 dull+ monocytes may produce IFN-c in response to IL-12 and IL-18 after differentiation into DCs and macrophages, although it is not directly evidenced. Recently, the significance of Gr-1 + monocytes in a variety of pathological conditions has garnered the attention of many investigators. In case of oral Salmonella infection, for example, Gr-1 + monocytes generating TNF-a and iNOS were numerically dominant over neutrophils in the infected tissues and were major producers of the effector molecules that were important in controlling the infection (50) . In myocardial infarction, Ly-6C + monocytes, which possess high proteinase activity and TNF-a production, digest damaged tissues and impaired healing (51) . Additionally, in a two-hit LPS-zymosan sepsis model, TNF-a-producing Gr-1 + monocytes are deeply involved in sepsis-related injury to the lungs (20) . Thus, Gr-1 dull+ cells may recruit to the inflammatory sites and play a crucial role during the progression of ALI/ARDS. In agreement with this notion, production of MCP-1, which is known to attract Gr-1 + monocytes (21, 52) , was enhanced in the lungs of both a-GalCer-sensitized mice and a-GalCer-sensitized and LPSchallenged mice (Supplementary Figure 2A and B is available at International Immunology Online).
To elucidate the roles of neutrophils and Gr-1 + monocytes, previous investigations have examined the effects of antiGr-1 mAb, which is known to deplete these leukocyte subsets, on the pathogenic conditions in various disease models including ALI (52, 53) . Here, we also adopted this approach by testing the effect of anti-Gr-1 mAb in the current model and found that depletion of Gr-1 + cells reduced the production of IFN-c and TNF-a, attenuated inflammatory responses and improved the survival rate in a-GalCer-sensitized LPS-treated mice. These results clearly demonstrate that both types of Gr-1 + cells are deeply involved in the progression of ALI/ARDS through their promotion of the synthesis of pro-inflammatory cytokines.
There has been no report investigating the role of NKT cells in the pathogenesis of human ARDS, and therefore, it is hard to mention whether NKT cells are involved in this pathogenic condition in clinical settings. Although the mechanism of NKT cells activation during development of ARDS has not been addressed, there could be the following possibilities: (i) a pathogenic microbe-derived glycolipid, like S. pneumoniae that is known to cause ARDS, may contribute to the activation of NKT cells, as recently reported by Kinjo et al. (54) ; (ii) a certain TLR ligand may stimulate the synthesis of IL-12, leading to the activation of NKT cells already weakly activated by some endogenous glycolipid antigen (55) and (iii) some glycolipid antigen from environment, like a soil bacterium, Sphingomonas-derived GSL, may be involved in the activation of NKT cells (56, 57) . Further investigations are required to clarify these issues.
In conclusion, we have demonstrated that pre-activation of iNKT cells led to drastic exacerbation of acute direct lung injury caused by intra-tracheal injection of LPS, as shown by the enormous production of inflammatory cytokines, severe inflammatory changes with hyaline membrane formation in the lungs and fatal clinical outcomes, all of which add up to a set of pathological conditions resembling that seen in human ARDS. Given that ARDS is one of the most intractable diseases, refractory even to advanced medical therapy, the current study will contribute significantly to our understanding of its pathogenic mechanism and to the development of an effective treatment for ARDS patients.
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